Hosted on MSN18h
Replicate’s rabies vaccine rivals Bavarian Nordic’s RavAlert at Phase I
The company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD
Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.
Malaysian Reserve16h
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence
Search for Chief Executive Officer to commence immediately SAN DIEGO and CALGARY, AB, Feb. 7, 2025 /PRNewswire/ -- Oncolytics ...
An unexpected mechanism regulates the immune response during parasitic infections
Researchers at the University of Liège (Belgium) have uncovered a previously unknown mechanism that regulates the immune ...
Frontiers11h
Advancements in Solid Tumor Immunotherapy: Enhancing Efficacy and Overcoming Resistance
In oncology, immunotherapy stands as a transformative approach for treating solid tumors, notably through pioneering treatments like immune checkpoint ...